Avid Bioservices Inc (CDMO)

[entdoc]

hope filled, methinks the handwriting on the I/O wall has been fully comprehended as it applies to advanced NSCLC. Actually, all these trials provide us with valuable information, but the incremental good vs. expense, and the possible negative PR for both products, could easily be judged to not be worth the price of admission. Imagine Durvalumab/Bavi combo being worse than SOC, etc. etc. I think the next thing for bavi is to find a stall in a well-financed stable that can afford to be in the race for the very long run. If PPHM continues to sit on Bavi, and if PPHM can move forward with Avid, Bavi will either emerge in the distant future with a role in chronic inflammatory conditions and early cancers, or be shelved for some long time.